Table 2 –

Associations between aspirin use at enrollment and prostate cancer risk among African American men in SCCS

	Events	PY	HR (95% CI)a	P value	HR (95% CI)b	P value
Overall
No use	690	162857	ref.		ref.
Any use	332	50057	1.11 (0.97–1.27)	0.14	1.07 (0.92–1.25)	0.40
Regular strength	136	25091	1.01 (0.84–1.21)	0.95	0.97 (0.78–1.19)	0.75
Less than daily	54	10934	1.00 (0.75–1.32)	0.97	1.03 (0.77–1.39)	0.84
Daily and more	269	37850	1.13 (0.98–1.31)	0.09	1.07 (0.91–1.26)	0.42
					P trend	0.41
≤3 years	189	30283	1.09 (0.92–1.28)	0.31	1.07 (0.89–1.28)	0.48
>3 years	135	18417	1.12 (0.93–1.36)	0.24	1.05 (0.84–1.30)	0.68
					P trend	0.45
TNM stage I/II
No use	420	162857	ref.		ref.
Any use	214	50057	1.12 (0.94–1.32)	0.21	1.03 (0.85–1.26)	0.74
Regular strength	90	25091	1.06 (0.84–1.34)	0.61	0.98 (0.75–1.28)	0.88
TNM stage III/IV
No use	90	162857	ref.		ref.
Any use	30	50057	0.83 (0.54–1.28)	0.40	1.00 (0.63–1.60)	0.98
Regular strength	9	25091	0.54 (0.27–1.07)	0.08	0.70 (0.34–1.41)	0.31
Gleason ≤ 7
No use	404	162857	ref.		ref.
Any use	181	50057	1.08 (0.90–1.29)	0.41	0.95 (0.77–1.17)	0.64
Regular strength	76	25091	0.98 (0.77–1.26)	0.88	0.90 (0.68–1.20)	0.48
Gleason ≥ 8
No use	86	162857
Any use	44	50057	1.15 (0.79–1.68)	0.46	1.36 (0.89–2.08)	0.15
Regular strength	16	25091	0.93 (0.54–1.59)	0.78	0.95 (0.51–1.75)	0.87
Aggressivec
No use	116	162857	ref.		ref.
Any use	53	50057	1.04 (0.74–1.46)	0.80	1.17 (0.80–1.71)	0.42
Regular strength	19	25091	0.82 (0.51–1.34)	0.44	0.84 (0.49–1.46)	0.54

Abbreviations: PY, person-years; HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis

^aHR was adjusted for age

^bHR was adjusted for age, enrollment year, education, income, family history of prostate cancer, smoking status, diabetes, BMI, BPH, PSA and DRE screening, acetaminophen, NSAIDs other than aspirin

^cT4 or N1 or M1 or Gleason score ≥ 8